Kristian Reich - Concepedia

Author

Kristian Reich

Also Known As

Andreas Pinter, Joachim Weis, K Reich, K. Reich, Katharina Reich, Kimberley Jackson, Kirk Barber, Kristian Reich, L. Puig, M Lpez

745

Publications

41.9K

Citations

103

H-Index

123

Concepts

All Affiliations

Dermatologikum Hamburg Universität Hamburg University Medical Center Hamburg-Eppendorf University of Lübeck University of Göttingen

About

Kristian Reich is an author at Dermatologikum Hamburg specializing in medicine, dermatology, and psoriatic arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	51	88	13.1K
2	Public Health	5	5	797
3	Arts	1	1	388
4	Engineering	1	1	159
5	Health Sciences	1	1	29

Kristian Reich

303

Publications

36.5K

Citations

H-Index

Page 1

	Year	Citations
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Richard G. Langley, Boni E. Elewski, Mark Lebwohl, New England Journal of Medicine	2014	1.9K
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Kim Papp, Richard G. Langley, Mark Lebwohl, The Lancet ImmunologyClinical TrialsClinical DermatologyPlacebo-controlled TrialDermatology	2008	1.3K
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Kristian Reich, Frank O. Nestlé, Kim Papp, The Lancet Infliximab InductionSystemic TreatmentPhase IiiClinical TrialsPsoriatic Arthritis	2005	1K
Definition of treatment goals for moderate to severe psoriasis: a European consensus Ulrich Mrowietz, Knud Kragballe, Kristian Reich, Archives of Dermatological Research	2010	868
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, New England Journal of Medicine	2016	818
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials C.E.M. Griffiths, Kristian Reich, Mark Lebwohl, The Lancet Randomised TrialsClinical TrialsClinical DermatologyDermatologyExperimental Dermatology	2015	815
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial Kristian Reich, April W. Armstrong, Peter Foley, Journal of the American Academy of Dermatology	2017	712
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris Delano Pathirana, AD Ormerod, P. Saïag, Journal of the European Academy of Dermatology and Venereology	2009	695
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Kim Papp, Kristian Reich, Craig L. Leonardi, Journal of the American Academy of Dermatology Autoimmune DiseaseMedicinePhase IiiClinical TrialsPlaque Psoriasis	2015	649
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials Kristian Reich, Kim Papp, Andrew Blauvelt, The Lancet Tildrakizumab Versus PlaceboResurface 1Clinical TrialsPsoriatic ArthritisClinical Dermatology	2017	540

Page 1